Item 7.01 Regulation FD Disclosure.
Agios expects to incorporate by reference the 2018-2019 Financial Statements in its proxy statement to be filed in connection with its previously announced sale of specified assets related to its oncology business. The 2018-2019 Financial Statements are being furnished solely for such purpose.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. Exhibit No. Description 99.1 The consolidated financial statements ofAgios Pharmaceuticals, Inc. and its subsidiaries as ofDecember 31, 2019 and 2018, including the consolidated balance sheets and the related consolidated statements of operations, of comprehensive loss, of stockholders' equity and of cash flows for the years then ended, including the related notes 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source